Form 4: Nuvation Bio CFO Philippe Sauvage Boosts Stake with Recent Stock Purchases
Insider Stock Purchase Report
Nuvation Bio Inc.'s Chief Financial Officer, Philippe Sauvage, has increased his direct ownership in the company through two open-market purchases of Class A Common Stock on June 16 and June 17, 2025.
Summary
- Philippe Sauvage, Chief Financial Officer of Nuvation Bio Inc. (NUVB), acquired additional shares of the company's Class A Common Stock through open-market transactions.
- On June 16, 2025, Mr. Sauvage purchased 3,300 shares at a price of $1.835 per share.
- On June 17, 2025, he purchased an additional 4,000 shares at a price of $1.79 per share.
- Following these transactions, Mr. Sauvage directly beneficially owns a total of 9,902 shares of Class A Common Stock.
- This total beneficial ownership includes 2,602 shares previously acquired on May 19, 2025, under the Issuer's 2021 Employee Stock Purchase Plan.
Sentiment
Score: 8
Explanation: The insider purchases by a key executive like the CFO typically signal strong internal confidence in the company's prospects, which is a positive indicator for investors.
Positives
- The Chief Financial Officer's open-market purchases of company stock indicate strong confidence in the company's current valuation and future prospects.
- These acquisitions increase Mr. Sauvage's direct beneficial ownership, further aligning his financial interests with those of the company's shareholders.
Future Outlook
The document does not contain any explicit forward-looking statements or guidance.
Management Comments
- While no direct verbal statements were made, the Chief Financial Officer's decision to purchase additional shares in the open market implicitly signals confidence in Nuvation Bio's current valuation and future prospects.
Industry Context
This Form 4 filing is a standard disclosure of insider trading activity, reflecting an executive's personal investment decision rather than broader industry trends. Such filings are common across all industries for publicly traded companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization for SEC Filings | A Power of Attorney was granted by Philippe Sauvage to Moses Makunje and Stephen Dang, and himself, to prepare and file SEC Forms 3, 4, 5, 13D, and 13G on his behalf. | 2025-03-19 | Streamlines the process for the CFO to comply with SEC reporting requirements for beneficial ownership and transactions, ensuring timely and accurate filings. |
Related Party Transactions
- Open-market purchases of Class A Common Stock by Chief Financial Officer Philippe Sauvage.
- Acquisition of shares under the Issuer's 2021 Employee Stock Purchase Plan by Philippe Sauvage.
Stakeholder Impact
- Shareholders: The insider buying by a key executive may instill greater confidence in the company's future, potentially leading to positive sentiment and share price performance.
- Employees: No direct impact is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 2025-03-19 | Date of Power of Attorney granting authority to file SEC forms on behalf of Philippe Sauvage. |
| 2025-05-19 | Date 2,602 shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan, contributing to the total beneficial ownership. |
| 2025-06-16 | Philippe Sauvage purchased 3,300 shares of Class A Common Stock at $1.835 per share. |
| 2025-06-17 | Philippe Sauvage purchased 4,000 shares of Class A Common Stock at $1.79 per share. |
| 2025-06-18 | Date the Form 4 was filed with the SEC. |
Recommendation
buyKeywords
Nuvation Bio Inc., NUVB, Philippe Sauvage, Chief Financial Officer, CFO, Insider Trading, Stock Purchase, SEC Form 4, Beneficial Ownership, Class A Common Stock, Employee Stock Purchase Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.